Current Research Activities and Interests
Dr. Cohen is the Medical Director of the the Health Economics and Technology Assessment (HETA) group of Saint Luke’s Mid America Heart Institute. This is a multidisciplinary research group that includes health economists, biostatisicians, decision analyst/modelers, and clinical scientists with a broad aim of improving health care by applying formal cost-effectiveness methodology to novel interventions for the diagnosis and treatment of cardiovascular disease. Currently, these efforts include a diverse range of projects including development of computer-based simulation models to aid in identifying appropriate targets for new technologies as well as primary economic data collection alongside pivotal clinical trials to evaluate cost-effectiveness of new therapeutic modalities (e.g., stents, glycoprotein 2b/3a blockers, vascular brachytherapy, etc.).
An additional focus of our research is in the extension of traditional cardiovascular outcomes research by collection of patient-centered outcomes (health status, quality of life) among patients undergoing treatment for cardiovascular disease. These efforts are aimed at identifying alternative treatments or patterns of care that are associated with improved long-term quality of life for patients with coronary heart disease, structural/valvular heart disease, as well as cardiac arrhythmias. Through primary data collection in a variety of clinical trial and practice settings, these data are valuable to patients, clinicians, and policy-makers who need to better understand the relationship between traditional “hard” clinical outcomes and overall quality of life among patients with cardiovascular disease.
Finally, we have had a longstanding interest in understanding the short- and long-term outcomes of new devices for percutaneous management of coronary artery disease and valvular heart disease and identifying the optimal target populations and techniques for these devices
Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, Appelwick J, Muratov V, Sleeper LA, Boineau R, Abdallah M, Cohen DJ. Cost-Effectiveness of Percutaneous Coronary Intervention with Drug Eluting Stents versus Bypass Surgery for Patients with Diabetes and Multivessel Coronary Artery Disease: Results from the FREEDOM Trial. Circulation 2013 (in press).
- Cohen DJ, Kuntz RE, Gordon SPF, Piana RN, Safian RD, McKay RG, Baim DS, Grossman W, Diver DJ. Predictors of long-term outcome after percutaneous balloon mitral valvuloplasty. N Engl J Med 1992; 327: 1329-35.
- Cohen DJ, Breall JA, Ho KKL, Kuntz RE, Goldman L, Baim DS, Weinstein MC. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: Use of a decision-analytic model. Circulation 1994;89:1859-1874.
- Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP, Zidar JP, Kuntz RE. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the SIRIUS trial. Circulation 2004;110:508-514.
- Ryan JW, Peterson ED, Chen AY, Roe MT, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV, Cohen DJ. Optimal timing of intervention in non-ST segment elevation acute coronary syndromes: Insights from the CRUSADE Registry. Circulation 2005;112:3049-57.
- Ryan J, Linde-Zwirble W, Engelhart L, Cooper L, Cohen DJ. Temporal trends in coronary revascularization procedures, outcomes, and costs in the bare metal stent and drug-eluting stent eras: Results from the US Medicare Program. Circulation 2009;119:952-61.
- Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned PCI: Results from the TRITON-TIMI 38 trial. Circulation 2010;71-79.
- Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Jeijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP on behalf of the SYNTAX Investigators. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med 2011;364;1016-26.
- Venkitachalam L, Lei Y, Stolker JM, Mahoney EM, Amin AP, Lindsey JB, Kennedy KF, Pencina MJ, Lopez JJ, Kleiman NS, Cohen DJ. Clinical and economic outcomes of liberal vs. selective drug-eluting stent use: Insights from temporal analysis of the multicenter EVENT registry. Circulation 2011;124:1028-37.
- Venkitachalam L, Lei Y, Magnuson EA, Chan PS, Stolker JM, Kennedy KF, Kleiman NS, Cohen DJ. Survival benefit with drug-eluting stents in observational studies: Fact or artifact? Circulation: Cardiovasc Qual Outcomes 2011;587-94.
- Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala JM, O’Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ.
Cost effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: Results from the PARTNER trial (Cohort B). Circulation 2012;125:1102-9.
- Arnold SV, Magnuson EA, Wang K, Serruys PW, Kappetein AP, Mohr FW,
Cohen DJ. Do differences in repeat revascularization explain the antianginal benefits of bypass surgery vs. percutaneous coronary intervention? Implications
for future treatment comparisons. Circulation: Cardiovasc Qual Outcomes 2012;5:267-75
- Reynolds MR, Magnuson EA, Lei Y, Wang K, Vilain K, Li H, Walczak J, Pinto DS, Thourani VH, Svennson LG, Mack MJ, Miller DC, Satler LE, Bavaria J, Smith CR, Leon MB, Cohen DJ. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in patients with severe aortic stenosis: Results from the PARTNER Trial (Cohort A). J Am Coll Cardiol 2012 (in press).